Literature DB >> 18293898

Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid.

Loretta Lazzarato1, Monica Donnola, Barbara Rolando, Elisabetta Marini, Clara Cena, Gabriella Coruzzi, Elena Guaita, Giuseppina Morini, Roberta Fruttero, Alberto Gasco, Stefano Biondi, Ennio Ongini.   

Abstract

A new class of products in which the phenol group of salicylic acid is linked to alkanoyl moieties bearing nitrooxy functions has been synthesized and studied for their polyvalent actions. The products were stable in acid and neutral media, while they were hydrolyzed in human serum. Their half-lives were dependent upon the structure of alkanoyl moieties. The products showed anti-inflammatory activities similar to aspirin when tested in the carrageenan-induced paw edema assay in the rat. Interestingly, unlike aspirin, they showed reduced or no gastrotoxicity in a lesion model in rats at equimolar doses. A number of them were able to inhibit platelet aggregation induced by collagen in human platelet-rich plasma. All of the products were capable of relaxing rat aortic strips precontracted with phenylephrine in a concentration-dependent manner. Selected members of this new class of nonsteroidal anti-inflammatory drugs might represent possible safer alternatives to aspirin in different clinical settings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18293898     DOI: 10.1021/jm701104f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Endothelial dysfunction in type 2 diabetes.

Authors:  A Natali; E Ferrannini
Journal:  Diabetologia       Date:  2012-01-20       Impact factor: 10.122

2.  Interference of H-bonding and substituent effects in nitro- and hydroxy-substituted salicylaldehydes.

Authors:  Aneta Jezierska-Mazzarello; Halina Szatyłowicz; Tadeusz Marek Krygowski
Journal:  J Mol Model       Date:  2011-04-27       Impact factor: 1.810

3.  Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.

Authors:  Paolo Gresele; Stefania Marzotti; Giuseppe Guglielmini; Stefania Momi; Silvia Giannini; Pietro Minuz; Paola Lucidi; Geremia B Bolli
Journal:  Diabetes Care       Date:  2010-03-18       Impact factor: 19.112

4.  NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Khosrow Kashfi
Journal:  ACS Med Chem Lett       Date:  2012-01-28       Impact factor: 4.345

5.  Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.

Authors:  Marco Migliore; Damien Habrant; Oscar Sasso; Clara Albani; Sine Mandrup Bertozzi; Andrea Armirotti; Daniele Piomelli; Rita Scarpelli
Journal:  Eur J Med Chem       Date:  2015-12-23       Impact factor: 6.514

6.  Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect.

Authors:  Wenping Zhao; Gerardo G Mackenzie; Onika T Murray; Zhiquan Zhang; Basil Rigas
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

Review 7.  The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications.

Authors:  Kearsley M Dillon; Ryan J Carrazzone; John B Matson; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2020-03-26       Impact factor: 5.858

8.  Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Khosrow Kashfi
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

9.  Mechanistic insights into a classic wonder drug--aspirin.

Authors:  Jinping Lei; Yanzi Zhou; Daiqian Xie; Yingkai Zhang
Journal:  J Am Chem Soc       Date:  2014-12-22       Impact factor: 15.419

Review 10.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development.

Authors:  Praveen P N Rao; Saad N Kabir; Tarek Mohamed
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.